Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells

In Vivo

Volumn 21, Issue 2, 2007, Pages 297-304

  Watanabe, Junichi ^a   Endo, Yoshio ^b   Shimada, Nami ^a   Natsume, Tsugitaka ^a   Sasaki, Takuma ^c   Kobayashi, Motohiro ^a  

^a ASKA Pharmaceutical Co Ltd   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Antivascular agent; Chick chorioallantoic membrane (CAM); Microtubule depolymerizing agent; Soblidotin; TZT 1027; Vascular tube formation

Indexed keywords

AURISTATIN PE; MESSENGER RNA; PROTEINASE; TRANSCRIPTION FACTOR;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CHICK EMBRYO; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; ZYMOGRAPHY;

EID: 34047212221     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K and Tsukagoshi S: Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 43: 1706-1718, 1995.
2. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K and Kobayashi M: Characterization of the interaction of TZT-1027, a potent antitumor agent with tubulin. Jpn J Cancer Res 91: 737-747, 2001.
3. Watanabe J, Natsume T, Fujio N, Miyasaka K and Kobayashi M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 5: 245-253, 2000.
4. Watanabe J, Minami M and Kobayashi M: Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res 26: 1973-1982, 2006.
5. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K and Tsukagoshi S: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
6. Natsume T, Watanabe J, Horiuchi T and Kobayashi M: Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. Anticancer Res 26: 1145-1152, 2006.
7. Watanabe J, Natsume T and Kobayashi M: Anti-vascular effects of TZT-1027 (Soblidotin) on murine Colon 26 adenocarcinoma. Cancer Sci Cancer Sci 97: 1410-1416, 2006.
8. Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T and Nakayama T: TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837-844, 2000.
9. Scfoeffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R and Satomi M: Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15: 671-679, 2004.
10. De Jonge MJA, Van der Gaast A, Planting AST, Van Dorn L, Lems A, Boot I, Wanders J, Satomi M and Verweij J: Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806-3813, 2005.
11. Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS and Steward WA: phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 17: 1313-1319, 2006.
12. Tozer GM, Kanthou C, Parkins CS and Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38, 2002.
13. Shepherd FA and Sridhar SS: Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41: 63-72, 2003.
14. Tanaka NG, Sakamoto N, Tohgo A, Nishiyama Y and Ogawa H: Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition. Exp Pathol 30: 143-150, 1986.
15. Oikawa T, Hirotani K and Shimamura M: Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic). J Antibiot 42: 1202-1204, 1989.
16. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y and Sasaki T: The significance of mRNA expression for vascular endothelial growth factor in primary lung cancer. Clin Cancer Res 2: 1411-1416, 1996.
17. Yanai S, Okada H and Saito K: Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. Pharm Res 12: 653-657, 1995.
18. Maeda M, Iigo M, Tsuda H, Fujita H, Yonemura Y, Nakagawa K, Endo Y and Sasaki T: Antimetastatic and antitumor effects of 2,4-diamino-6-(pyridine-4-yl)-1,3,5- triazine (4PyDAT) on the high lung metastatic colon 26 tumor in mice. Anticancer Drug Des 15: 217-223, 2000.
19. Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB and Shapiro RL: Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res 77: 126-131, 1998.
20. Iwasaka C, Tanaka K, Abe M and Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169: 522-531, 1996.
21. Hudson MA and McReynolds LM: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 89: 709-717, 1997.
22. Hudson MA and McReynold LM: Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines. Adv Exp Med Biol 462: 399-412, 1999.
23. Kageyama Y, Kawakami S, Fujii Y, Kihara K and Oshima H: Bacillus Calmette-Guerin enhances production and secretion of type IV collagenases in peripheral blood mononuclear cells. Jpn J Cancer Res 88: 281-288, 1997.
24. Hamasaki T, Hattori T, Kimura G and Nakazawa N: Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells. Urol Res 26: 371-376, 1998.
25. Bostrom PJ, Ravanti L, Reunanen N, Aaltonen V, Soderstrom KO, Kahari VM and Laato M: Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. Int J Cancer 88: 417-423, 2000.
26. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
27. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K and Sato Y: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289: 39-43, 2001.